Skip to main content
. Author manuscript; available in PMC: 2020 Aug 25.
Published in final edited form as: Cancer Immunol Immunother. 2017 Sep 13;67(1):47–60. doi: 10.1007/s00262-017-2059-y

Fig. 1.

Fig. 1

Potent local and systemic anti-tumor effects of low-dose (30 μg) triple combination immunotherapy. a Treatment scheme: a dual tumor mouse model was used for MC38 (colon cancer) and A20 (B-cell lymphoma) models in C57BL/6 and BALB/c mice, respectively. Treatment was administered by intratumoral injection to the left tumor consisting of 6 (MC38) or 4 (A20) biweekly injections of the triple combination αCTLA4, αCD137, and αOX40 at a dose of 30 μg each, started approximately day 8 after tumor inoculation when tumors were 7–10 mm diameter. Tumor growth measure by caliper of MC38 or A20 injected (b, c) or non-injected site (d, e). Survival curves for MC38 (f) or A20 (g) models are shown. h–k Representative photos of the treatment groups at Day 19 of tumor inoculation. ‘*’ denotes p < .05 (unpaired t test for tumor growth and Mantel Cox for survival). Values for b–e are mean ± SEM. n = 10 (MC38) and 7 (A20) per group